Streetbeat News

Stock Prices

AMZN

The article suggests that growth investors should consider buying Amazon (AMZN) due to its strong growth potential and solid growth attributes, which could lead to exceptional returns.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

BCRX

BioCryst Pharmaceuticals is recommended as a 'Buy' due to the success and growth potential of its drug ORLADEYO, despite competition and a one-dimensional revenue stream. Q3 2024 results showed a modest revenue beat but a slight earnings miss, causing a 13% stock drop. ORLADEYO's revenue is expected to reach $1 billion annually by 2029.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

RDDT

Reddit's stock hits record highs following the announcement of a new AI search tool, as discussed by Josh Brown on CNBC's 'Halftime Report'.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

SOFI

SoFi's stock has doubled over the past three months, but Bank of America (BofA) now considers it overvalued. BofA describes the stock as 'priced to perfection' and highlights concerns about reduced visibility into tech deals and fair-value accounting.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

PAY

Paymentus (PAY) is highlighted as a strong growth investment opportunity due to its solid growth attributes, suggesting it could outperform the market.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

NVDA

Nvidia provides insights into the ongoing U.S.-China trade tensions, suggesting that markets may be underestimating the impact of Biden's export restrictions and Trump's tariff threats.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

ZETA

Levi & Korsinsky has announced a class action lawsuit against Zeta Global Holdings Corp. (NYSE:ZETA) with a lead plaintiff deadline of January 21, 2025. Investors who suffered losses are encouraged to seek potential recovery under federal securities laws.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

CORT

Corcept Therapeutics (CORT) is highlighted as a strong growth stock with potential for exceptional returns due to its solid growth attributes.

Portfolio Pulse from

December 09, 2024 | 7:00 pm

EXEL

Exelixis (EXEL) is highlighted as a strong growth stock with potential to outperform the market due to its above-average financial growth.

Portfolio Pulse from

December 09, 2024 | 7:00 pm